Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors (NCT00695032) | Clinical Trial Compass
SuspendedNot Applicable
Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors
France80 participantsStarted 2007-10
Plain-language summary
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is evaluating kidney damage in patients receiving cisplatin and ifosfamide for solid tumors.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Diagnosis of a solid tumor
* Any location allowed
* Metastatic disease allowed
* Planned treatment comprising cisplatin and/or ifosfamide as standard chemotherapy
PATIENT CHARACTERISTICS:
Inclusion criteria:
* Life expectancy \> 3 months
* Creatinine clearance ≥ 60 mL/min
* Must be available for follow up
* Not pregnant or nursing
* Not under guardianship or in prison
Exclusion criteria:
* Prior drug-related nephrotoxicity
* Acute, uncontrolled urinary infection or \> 48-hours
* Pre-existing hemorrhagic cystitis
* Weak bladder
* Bilateral obstruction of urinary tract
* Insufficient, severe bone marrow hypoplasia
* Cardiorespiratory condition contraindicating hyperhydration
* Hearing impairment
* Hypersensitivity to cisplatin or products containing platinum
* Major psychiatric condition (severe depression, psychosis, dementia)
PRIOR CONCURRENT THERAPY:
* No prior yellow fever vaccine, live attenuated vaccine, or phenytoin
* No concurrent participation in another biomedical study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Evolution of different biomarkers
2
Sensitivity, specificity, and predictive value (positive and negative) of different markers